These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25497672)

  • 81. Anticancer Effects of Wild Mountain
    Patti F; Palmioli A; Vitalini S; Bertazza L; Redaelli M; Zorzan M; Rubin B; Mian C; Bertolini C; Iacobone M; Armanini D; Barollo S; Airoldi C; Iriti M; Pezzani R
    Front Pharmacol; 2019; 10():1647. PubMed ID: 32116670
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines.
    Zhou J; Oliveira P; Li X; Chen Z; Bepler G
    J Nucleic Acids; 2010 Sep; 2010():597098. PubMed ID: 20976259
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
    Theile D; Haefeli WE; Weiss J
    Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network.
    Faron M; Naman A; Delahousse J; Hescot S; Hadoux J; Castinetti F; Drui D; Renoult-Pierre P; Libe R; Lamartina L; Leboulleux S; Al-Ghuzlan A; Lombès M; Paci A; Baudin E;
    J Endocrinol Invest; 2024 Aug; ():. PubMed ID: 39172357
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Morphological predictors of the efficacy of mitotane therapy in adrenocortical cancer].
    Tkachuk AV; Beltsevich DG; Porubayeva EE; Urusova LS
    Probl Endokrinol (Mosk); 2023 Jan; 68(6):76-88. PubMed ID: 36689714
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Effects of o,p'-DDE, a Mitotane Metabolite, in an Adrenocortical Carcinoma Cell Line.
    Bach C; Corso CR; Veiga AA; Paraizo MM; de Souza LM
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558937
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer.
    Liu Z; Xing L; Zhu Y; Shi P; Deng G
    Heliyon; 2022 Jun; 8(6):e09643. PubMed ID: 35711974
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies.
    Lo Iacono M; Puglisi S; Perotti P; Saba L; Petiti J; Giachino C; Reimondo G; Terzolo M
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771418
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Prognostic and predictive role of a metabolic rate-limiting enzyme signature in hepatocellular carcinoma.
    Wang Z; Fu Y; Xia A; Chen C; Qu J; Xu G; Zou X; Wang Q; Wang S
    Cell Prolif; 2021 Oct; 54(10):e13117. PubMed ID: 34423480
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study.
    Altieri B; Sbiera S; Herterich S; De Francia S; Della Casa S; Calabrese A; Pontecorvi A; Quinkler M; Kienitz T; Mannelli M; Canu L; Angelousi A; Chortis V; Kroiss M; Terzolo M; Fassnacht M; Ronchi CL
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32033200
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
    van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196
    [TBL] [Abstract][Full Text] [Related]  

  • 92. CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
    Germano A; Saba L; De Francia S; Rapa I; Perotti P; Berruti A; Volante M; Terzolo M
    PLoS One; 2018; 13(5):e0196931. PubMed ID: 29734384
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms.
    Mete O; Asa SL; Giordano TJ; Papotti M; Sasano H; Volante M
    Endocr Pathol; 2018 Jun; 29(2):137-149. PubMed ID: 29542002
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas.
    Hadjadj D; Kim SJ; Denecker T; Ben Driss L; Cadoret JC; Maric C; Baldacci G; Fauchereau F
    Aging (Albany NY); 2017 Dec; 9(12):2695-2716. PubMed ID: 29283884
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.
    Germano A; Rapa I; Duregon E; Votta A; Giorcelli J; Buttigliero C; Scagliotti GV; Volante M; Terzolo M; Papotti M
    Endocr Pathol; 2017 Jun; 28(2):95-102. PubMed ID: 28271381
    [TBL] [Abstract][Full Text] [Related]  

  • 96. RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization.
    Germano A; Rapa I; Volante M; De Francia S; Migliore C; Berruti A; Papotti M; Terzolo M
    Mol Cell Endocrinol; 2015 Feb; 401():105-10. PubMed ID: 25497672
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
    Hermsen IG; Fassnacht M; Terzolo M; Houterman S; den Hartigh J; Leboulleux S; Daffara F; Berruti A; Chadarevian R; Schlumberger M; Allolio B; Haak HR; Baudin E
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1844-51. PubMed ID: 21470991
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
    Hescot S; Paci A; Seck A; Slama A; Viengchareun S; Trabado S; Brailly-Tabard S; Al Ghuzlan A; Young J; Baudin E; Lombès M
    Horm Cancer; 2014 Oct; 5(5):312-23. PubMed ID: 25026941
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.
    Volante M; Terzolo M; Fassnacht M; Rapa I; Germano A; Sbiera S; Daffara F; Sperone P; Scagliotti G; Allolio B; Papotti M; Berruti A
    Clin Cancer Res; 2012 Jun; 18(12):3452-61. PubMed ID: 22547773
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Mitotane treatment for adrenocortical carcinoma: an overview.
    De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
    Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.